Research Analysts’ Weekly Ratings Changes for Neurogene (NGNE)

by · The Cerbat Gem

A number of firms have modified their ratings and price targets on shares of Neurogene (NASDAQ: NGNE) recently:

  • 11/12/2024 – Neurogene had its price target lowered by analysts at BMO Capital Markets from $65.00 to $60.00. They now have an “outperform” rating on the stock.
  • 11/12/2024 – Neurogene had its price target raised by analysts at Leerink Partners from $45.00 to $72.00. They now have an “outperform” rating on the stock.
  • 11/12/2024 – Neurogene had its price target raised by analysts at Robert W. Baird from $54.00 to $72.00. They now have an “outperform” rating on the stock.
  • 11/12/2024 – Neurogene had its price target raised by analysts at Stifel Nicolaus from $44.00 to $60.00. They now have a “buy” rating on the stock.
  • 11/12/2024 – Neurogene had its price target raised by analysts at HC Wainwright from $49.00 to $55.00. They now have a “buy” rating on the stock.

Neurogene Stock Performance

NASDAQ:NGNE traded down $0.46 on Thursday, hitting $39.20. 610,645 shares of the stock were exchanged, compared to its average volume of 139,746. Neurogene Inc. has a 52 week low of $12.49 and a 52 week high of $74.49. The company’s 50-day moving average price is $47.01 and its 200 day moving average price is $40.12.

Institutional Investors Weigh In On Neurogene

Hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in Neurogene by 912.4% during the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after buying an additional 659,515 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Neurogene by 906.5% in the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock worth $25,831,000 after acquiring an additional 457,062 shares during the last quarter. Jennison Associates LLC bought a new stake in shares of Neurogene in the 3rd quarter valued at about $3,300,000. Integral Health Asset Management LLC bought a new position in shares of Neurogene during the 2nd quarter worth approximately $2,547,000. Finally, Driehaus Capital Management LLC raised its position in shares of Neurogene by 123.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company’s stock valued at $3,719,000 after purchasing an additional 56,533 shares during the last quarter. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

See Also